HRP20191929T1 - Liječenje progresivne osificirajuće fibrodisplazije - Google Patents

Liječenje progresivne osificirajuće fibrodisplazije Download PDF

Info

Publication number
HRP20191929T1
HRP20191929T1 HRP20191929TT HRP20191929T HRP20191929T1 HR P20191929 T1 HRP20191929 T1 HR P20191929T1 HR P20191929T T HRP20191929T T HR P20191929TT HR P20191929 T HRP20191929 T HR P20191929T HR P20191929 T1 HRP20191929 T1 HR P20191929T1
Authority
HR
Croatia
Prior art keywords
antibody
use according
activin
seq
heavy
Prior art date
Application number
HRP20191929TT
Other languages
English (en)
Croatian (hr)
Inventor
Sarah J. Hatsell
Aris N. Economides
Vincent J. Idone
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of HRP20191929T1 publication Critical patent/HRP20191929T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
HRP20191929TT 2014-09-12 2015-09-14 Liječenje progresivne osificirajuće fibrodisplazije HRP20191929T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462049869P 2014-09-12 2014-09-12
US201562141775P 2015-04-01 2015-04-01
EP15775835.0A EP3191512B1 (en) 2014-09-12 2015-09-14 Treatment of fibrodysplasia ossificans progressiva
PCT/US2015/000100 WO2016039796A2 (en) 2014-09-12 2015-09-14 Treatment of fibrodysplasia ossificans progressiva

Publications (1)

Publication Number Publication Date
HRP20191929T1 true HRP20191929T1 (hr) 2020-01-10

Family

ID=54207748

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191929TT HRP20191929T1 (hr) 2014-09-12 2015-09-14 Liječenje progresivne osificirajuće fibrodisplazije

Country Status (29)

Country Link
US (3) US20160075772A1 (enExample)
EP (2) EP3191512B1 (enExample)
JP (1) JP6560341B2 (enExample)
KR (1) KR102564079B1 (enExample)
CN (1) CN107106648B (enExample)
AU (1) AU2015315829B2 (enExample)
CA (1) CA2960950C (enExample)
CL (2) CL2017000603A1 (enExample)
CY (1) CY1122188T1 (enExample)
DK (1) DK3191512T3 (enExample)
ES (1) ES2739605T3 (enExample)
HR (1) HRP20191929T1 (enExample)
HU (1) HUE046558T2 (enExample)
IL (1) IL251063B (enExample)
LT (1) LT3191512T (enExample)
MA (1) MA40621B1 (enExample)
ME (1) ME03541B (enExample)
MX (1) MX382026B (enExample)
MY (1) MY179654A (enExample)
NZ (1) NZ730773A (enExample)
PL (1) PL3191512T3 (enExample)
PT (1) PT3191512T (enExample)
RS (1) RS59412B1 (enExample)
SG (2) SG11201701913SA (enExample)
SI (1) SI3191512T1 (enExample)
SM (1) SMT201900584T1 (enExample)
TW (1) TWI688402B (enExample)
WO (1) WO2016039796A2 (enExample)
ZA (1) ZA201702112B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2780368T3 (pl) 2011-11-14 2018-06-29 Regeneron Pharmaceuticals, Inc. Kompozycje i sposoby do zwiększania masy mięśni i siły mięśni poprzez swoiste antaganizowanie GDF8 i/lub aktywiny A
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
EP3283519A1 (en) 2015-04-15 2018-02-21 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
MX2017013520A (es) 2015-04-22 2018-05-22 Alivegen Usa Inc Nuevas proteinas hibridas de bloqueo del ligando actriib para tratar enfermedades de atrofia muscular.
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
EP3415527B1 (de) * 2017-06-14 2025-12-10 Kymab Ltd. Verwendung der extrazellulären domäne des transferrinrezeptor 2 zur diagnostik und behandlung von primär und sekundär sklerosierenden erkrankungen
JP7579706B2 (ja) 2018-03-01 2024-11-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 体組成を変更するための方法
CN111836643A (zh) * 2018-03-05 2020-10-27 学校法人埼玉医科大学 用于治疗或预防异位骨化的药物组合物
WO2019195796A1 (en) 2018-04-06 2019-10-10 Regeneron Pharmaceuticals, Inc. A leptin receptor agonist antibody for use in treating a metabolic dysfunction or hypoleptinemia
CA3099441A1 (en) 2018-06-13 2019-12-19 Regeneron Pharmaceuticals, Inc. A rodent model of fibrodysplasia ossificans progressiva
US20210214456A1 (en) 2018-06-13 2021-07-15 Kymab Limited Antagonists and agonists of the transferrin receptor-2 for use in the treatment of diseases of the bone
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
EA202190418A1 (ru) * 2018-08-02 2021-06-23 Дайн Терапьютикс, Инк. Мышечно-специфические комлексы и их применение в лечении прогрессирующей оссифицирующей фибродисплазии
JP2021533200A (ja) 2018-08-02 2021-12-02 ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. 顔面・肩甲・上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用
JP7512272B2 (ja) * 2018-10-23 2024-07-08 ケロス セラピューティクス インコーポレイテッド Ａｌｋ２抗体及びその使用方法
MX2021007394A (es) * 2018-12-18 2021-07-15 Regeneron Pharma Composiciones y metodos para aumentar el peso corporal y la masa muscular magra mediante el uso de antagonistas contra el receptor de leptina, gdf8 y activina a.
EP4087652A1 (en) * 2020-01-08 2022-11-16 Regeneron Pharmaceuticals, Inc. Treatment of fibrodysplasia ossificans progressiva
WO2021142260A1 (en) * 2020-01-10 2021-07-15 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for modulation of acvr1
US12472253B2 (en) * 2020-06-18 2025-11-18 Regeneron Pharmaceuticals, Inc. Activin a antibody formulations and methods of use thereof
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
MX2023005565A (es) * 2020-11-11 2024-02-23 Hq Han Antagonistas bifuncionales de activina/tgf-beta y rankl y usos de los mismos.
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
IL310810A (en) * 2021-09-03 2024-04-01 Laekna Therapeutics Shanghai Co Ltd Anti-ACVR2A antibodies and uses thereof
WO2024234869A1 (en) * 2023-05-15 2024-11-21 Immunecare Biopharmaceuticals (Shanghai) Co., Ltd. Recombinant fusion protein for treatment of pulmonary hypertension

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
CN100405399C (zh) 1999-02-05 2008-07-23 三星电子株式会社 图像纹理恢复方法及其装置
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
DK1709081T3 (da) 2004-01-16 2011-06-06 Regeneron Pharma Fusionspolypeptider, der kan aktivere receptorer
ES2561048T3 (es) 2004-07-23 2016-02-24 Acceleron Pharma Inc. Polipéptidos del receptor ActRII
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8859752B2 (en) * 2006-04-18 2014-10-14 The Trustees Of The University Of Pennsylvania SIRNA-based therapy of Fibrodyplasia Ossificans Progressiva (FOP)
JP2010502220A (ja) * 2006-09-05 2010-01-28 メダレックス インコーポレーティッド 骨形態形成タンパク質およびその受容体に対する抗体ならびにその使用方法
CL2007002567A1 (es) * 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
TW201907946A (zh) * 2007-02-02 2019-03-01 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
CN101861161B (zh) 2007-09-18 2017-04-19 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
JP5270913B2 (ja) 2007-12-26 2013-08-21 サンゴバン・ティーエム株式会社 高電気抵抗高ジルコニア鋳造耐火物
CA2718403A1 (en) * 2008-03-13 2009-09-17 The General Hospital Corporation Inhibitors of the bmp signaling pathway
WO2009137075A1 (en) 2008-05-06 2009-11-12 Acceleron Pharma Inc. Anti-activin antibodies and uses for promoting bone growth
EP2583692A4 (en) * 2010-06-18 2014-11-26 Lsip Llc HEMMER OF THE EXPRESSION OF DOMINANT ALLELES
WO2013063536A1 (en) * 2011-10-27 2013-05-02 Acceleron Pharma, Inc. Actriib binding agents and uses thereof
PL2780368T3 (pl) * 2011-11-14 2018-06-29 Regeneron Pharmaceuticals, Inc. Kompozycje i sposoby do zwiększania masy mięśni i siły mięśni poprzez swoiste antaganizowanie GDF8 i/lub aktywiny A
WO2014051109A1 (ja) 2012-09-28 2014-04-03 協和発酵キリン株式会社 抗ヒトｂｍｐ９抗体および該抗体を有効成分とする異所性骨化疾患の治療剤
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
JP6601687B2 (ja) 2014-03-31 2019-11-06 大日本住友製薬株式会社 進行性骨化性線維異形成症の予防剤及び治療剤
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
AR103675A1 (es) * 2015-02-13 2017-05-24 Sorrento Therapeutics Inc Anticuerpos anti-ctla4 terapéuticos
US20160319009A1 (en) 2015-04-29 2016-11-03 Regeneron Pharmaceuticals, Inc. Treatment of fibrodysplasia ossificans progressiva

Also Published As

Publication number Publication date
WO2016039796A2 (en) 2016-03-17
JP6560341B2 (ja) 2019-08-14
PL3191512T3 (pl) 2020-01-31
TWI688402B (zh) 2020-03-21
CN107106648B (zh) 2021-06-11
BR112017004812A2 (pt) 2017-12-12
EP3604335A1 (en) 2020-02-05
SMT201900584T1 (it) 2019-11-13
SG10201902175RA (en) 2019-04-29
SI3191512T1 (sl) 2019-09-30
EP3191512A2 (en) 2017-07-19
MA40621B1 (fr) 2019-11-29
US20160075772A1 (en) 2016-03-17
MY179654A (en) 2020-11-11
AU2015315829A1 (en) 2017-04-27
PT3191512T (pt) 2019-09-26
MX382026B (es) 2025-03-13
WO2016039796A3 (en) 2016-06-16
DK3191512T3 (da) 2019-08-12
MA40621A (fr) 2017-07-19
US20200115440A1 (en) 2020-04-16
AU2015315829B2 (en) 2021-05-27
CN107106648A (zh) 2017-08-29
JP2017528476A (ja) 2017-09-28
US20180111983A1 (en) 2018-04-26
CA2960950A1 (en) 2016-03-17
EP3191512B1 (en) 2019-07-24
NZ730773A (en) 2022-07-01
LT3191512T (lt) 2019-09-10
US11407822B2 (en) 2022-08-09
RS59412B1 (sr) 2019-11-29
CL2018002962A1 (es) 2018-12-28
ME03541B (me) 2020-07-20
HUE046558T2 (hu) 2020-03-30
KR20170052666A (ko) 2017-05-12
IL251063B (en) 2022-08-01
SG11201701913SA (en) 2017-04-27
ZA201702112B (en) 2018-05-30
KR102564079B1 (ko) 2023-08-08
MX2017003175A (es) 2017-06-06
CL2017000603A1 (es) 2017-10-06
TW201625302A (zh) 2016-07-16
IL251063A0 (en) 2017-04-30
ES2739605T3 (es) 2020-02-03
CA2960950C (en) 2023-03-14
CY1122188T1 (el) 2020-11-25

Similar Documents

Publication Publication Date Title
HRP20191929T1 (hr) Liječenje progresivne osificirajuće fibrodisplazije
IL287823A (en) Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders
MX375953B (es) Moleculas de anticuerpo que se unen a tim-3 y usos de las mismas.
EP3389699A4 (en) CHIMERIC AND HUMANIZED MONOCLONAL ANTIBODIES TO HUMAN CTLA4 AND USES THEREOF
NZ739750A (en) Anti-tigit antibodies and methods of use
BR112017017927A2 (pt) receptores quiméricos de antígenos anti-dll3 e métodos de uso
IL254533A0 (en) Systems and methods for heart valve therapy
LT3274370T (lt) Antikūnai prieš ceacam6 ir jų panaudojimas
EA201691488A1 (ru) Молекулы антител против pd-1 и их применения
SG11201708516YA (en) Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
MX389663B (es) Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
BR112016014952A2 (pt) Inibição direcionada de tgfbeta
CY1125400T1 (el) Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων
IL261859B (en) Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
PT3286223T (pt) Recetores de antigénio quimérico do antigénio do mieloma kappa e suas utilizações
SG11201605691VA (en) Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
MX391141B (es) Anticuerpos anti-ceramida.
EA201792058A1 (ru) Виротерапия комбинацией антител
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
SI3445785T1 (sl) Humanizirana protitelesa proti CLEVER-1 in njihova uporaba
MX2016009597A (es) Terapias para el influenzavirus a subtipo h7n9.
IL287008A (en) Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
BR112018068671A2 (pt) anticorpos monoclonais neutralizantes para il-25 e usos dos mesmos
MA40536A (fr) Anticorps anti-alpha v bêta 5 humanisés et leurs utilisations